Lung Transplantation: Advances in Immunosuppression

Errol L. Bush, Shu S. Lin

Research output: Contribution to journalReview articlepeer-review

Abstract

Since the advent of various novel immunosuppressants, including tacrolimus, rapamycin, and daclixumab, expanding variations of protocols have been developed. Little evidence exists to substantially support a single agent over another, or a combination regimen protocol over another. Therefore, the principles and the goals of immunosuppression in lung transplantation recipients will remain moving targets and continue to evolve, and the use of large-scale, multi-institutional clinical trials is imperative to develop optimal immunosuppressive strategies.

Original languageEnglish (US)
Pages (from-to)421-433
Number of pages13
JournalThoracic surgery clinics
Volume16
Issue number4
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Lung Transplantation: Advances in Immunosuppression'. Together they form a unique fingerprint.

Cite this